Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injury—Opinion from the Front Lines


      Differentiating patients with type 1 and type 2 myocardial infarction (MI) and acute non-ischemic myocardial injury continues to be a problem for many clinicians. Type 1 MI is the most easily defined. It involves the rise and fall of blood troponin measurements (only falling values if the patient arrives late) with an appropriate clinical observation consistent with myocardial ischemia. Diagnosis and therapy of type 1 MI are well understood and usually present no problem to the physician. The clinical scenarios leading to type 2 MI and non-ischemic myocardial injury are, however, often fraught with greater degrees of uncertainty. In addition, therapy for these latter 2 entities is poorly defined. This review will present 3 patient scenarios that should help clinicians understand the difference between these 3 entities as well as possible therapeutic interventions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Thygesen K
        • Alpert JS
        • White HD
        • et al.
        Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction.
        Circulation. 2007; 116 (Eur Heart J. 2007; 28:2525-2538. J Am Coll Cardiol. 2007; 50: 2173-2195): 2634-2653
        • Thygesen K
        • Alpert JS
        • Jaffe AS
        • Simoons ML
        • Chaitman BR
        • White HD
        • Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction
        Third universal definition of myocardial infarction.
        Eur Heart J. 2012; 33: 2551-2567
        • Thygesen K
        • Alpert JS
        • Jaffe AS
        • et al
        Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction.
        Circulation. 2018; 138: e618-e651
        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • et al.
        ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 130: e344-e426
        • Kaier TE
        • Alaour B
        • Marber M
        Cardiac troponin and defining myocardial infarction.
        Cardiovasc Res. 2021; 117: 2203-2215.
        • Sandoval Y
        • Jaffe AS.
        Type 2 myocardial infarction: JACC review topic of the week.
        J Am Coll Cardiol. 2019; 73: 1846-1860
        • Rafiudeen R
        • Barlis P
        • White HD
        • van Gaal W
        Type 2 MI and myocardial injury in the era of high-sensitivity troponin.
        Eur Cardiol. 2022 Feb 17; 17: e03
        • Chung MK
        • DA Zidar
        • Bristow MR
        • et al.
        COVID-19 and cardiovascular disease: from bench to bedside.
        Circ Res. 2021; : 1214-1236
        • Sandoval Y
        • Januzzi Jr, JL
        • Jaffe JS
        Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week.
        J Am Coll Cardiol. 2020; 76: 1244-1258
        • McFadyen JD
        • Stevens H
        • Peter K
        The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications.
        Circ Res. 2020; 127: 571-587
        • Giannis D
        • Douketis JD
        • Spyropoulos AC
        Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?.
        Eur J Intern Med. 2022; 96: 13-16
        • DeFilippis AP
        • Chapman AR
        • Mills NL
        • et al.
        Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury.
        Circulation. 2019; 140: 1661-1678